Search results
Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Growth Stock
Zacks via Yahoo News· 1 month agoTaking full advantage of the stock market and investing with confidence are common goals for new and...
Vertex (VRTX) Rises 16.5% YTD: Time to Bet On the Stock?
Zacks via Yahoo News· 1 month agoVertex Pharmaceuticals Incorporated VRTX has been witnessing strong revenue growth, regulatory...
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Zacks via Yahoo News· 1 month agoVertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is...
Vertex Pharmaceuticals (VRTX) is a Top-Ranked Growth Stock: Should You Buy?
Zacks via Yahoo News· 2 years agoFor new and old investors, taking full advantage of the stock market and investing with confidence...
Top Stock Reports for JPMorgan Chase, Elevance Health & Vertex Pharmaceuticals
Zacks via Yahoo News· 1 year agoToday's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase &...
Vertex (VRTX) Stock Poised Well for Growth in 2023: Here's Why
Zacks via Yahoo News· 1 year agoVertex Pharmaceuticals (VRTX) stock is likely to be driven by several catalysts this year. Multiple...
The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex...
Zacks via Yahoo News· 2 years agoFor Immediate Release Chicago, IL – August 12, 2022 – Zacks.com announces the list of stocks...
The Zacks Analyst Blog Highlights Mastercard, Cisco, PayPal, Vertex Pharmaceuticals and ICICI Bank
Zacks via Yahoo News· 2 years agoFor Immediate Release Chicago, IL – August 23, 2022 – Zacks.com announces the list of stocks...
Vertex (VRTX) Gets EU Nod for Kaftrio Use in 2-5 Year Kids
Zacks via Yahoo News· 8 months agoVertex Pharmaceuticals Incorporated VRTX announced that the European Commission (“EC”) has approved...
Vertex (VRTX) to Report Q3 Earnings: What's in the Cards?
Zacks via Yahoo News· 2 years agoOn Vertex Pharmaceuticals' (VRTX) Q3 earnings call, investors' focus will likely be on the sales...